natgillin/translations-raw huggingface dataset:
Alvorlige allergiske reaktioner eller hudreaktioner Nogle personer, der tager Celsentri, udvikler alvorlige og livstruende hudreaktioner og allergiske reaktioner. 
Some people taking CELSENTRI have developed severe and life-threatening skin reactions and allergic reactions.
Pakningen indeholder en oral doseringssprøjte og en sprøjteadapter, som skal isættes flasken inden brug. 
The pack includes an oral applicator and a bottle-adapter, which should be fitted in the bottle before use.
Der er udført populationsanalyser af fase 1/2a- og fase 3-studierne (16-65 år), og der er ikke fundet nogen påvirkning, som kan tilskrives alder (se pkt.4.2). 
Population analysis of the Phase 1/2a and Phase 3 studies (16-65 years of age) has been conducted and no effect of age have been observed (see section 4.2).
Pakningsstørrelser og yderligere oplysninger Celsentri indeholder 
Contents of the pack and other information What CELSENTRI contains
Maraviroc-dosering var baseret på legemsoverfladeareal, og doserne blev justeret på baggrund af, om forsøgspersonerne fik potente CYP3A-hæmmere og/eller -induktorer. 
Maraviroc dosing was based on body surface area and doses were adjusted based on whether the subject was receiving potent CYP3A inhibitors and/or inducers.
Hos behandlingsnaive patienter var forekomsten af laboratorieanormaliteter (grad 3 og 4), bestemt udfra ACTG-kriterier, ens mellem maraviroc- og efavirenz-grupperne. 
In treatment-naïve patients, the incidence of grade 3 and 4 laboratory abnormalities using ACTG criteria was similar among the maraviroc and efavirenz treatment groups.
Sammenligning af eksponering i historiske kontroller tyder på, at Celsentri 300 mg 2 gange daglig og nevirapin kan anvendes samtidigt uden dosisjustering. 
Comparison to exposure in historical controls suggests that CELSENTRI 300 mg twice daily and nevirapine can be co-administered without dose adjustment.
Elvitegravir som monokomponentlægemiddel er kun indiceret i kombination med visse ritonavirboostede PI'er. 
Elvitegravir as a single agent is indicated only in combination with certain ritonavir boosted PIs.
Den orale doseringssprøjte medfølger for præcis opmåling af den ordinerede dosis oral opløsning. 
The oral applicator is provided for accurate measurement of the prescribed dose of oral solution.
På nuværende tidspunkt er der ikke dokumentation vedrørende genanvendelse af Celsentri til patienter, der i øjeblikket er smittet kun med hiv 1-virus med CCR5-tropisme, men i anamnesen har haft manglende effekt af Celsentri (eller andre CCR5-antagonister) med en CXCR4 eller dual/mixed tropisme. 
There are currently no data regarding the reuse of CELSENTRI in patients that currently have only CCR5-tropic HIV-1 detectable, but have a history of failure on CELSENTRI (or other CCR5 antagonists) with a CXCR4 or dual/mixed tropic virus.
Samtidig administration af Celsentri og fosamprenavir/ritonavir kan ikke tilrådes. 
Concomitant use of CELSENTRI and fosamprenavir/ritonavir is not recommended.
In vitro studier har vist, at maraviroc ved klinisk relevante koncentrationer ikke hæmmer OATP1B1, MRP2 eller nogen af de vigtige P450-enzymer (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 og CYP3A4). 
In vitro studies have shown that maraviroc does not inhibit OATP1B1, MRP2 or any of the major P450 enzymes at clinically relevant concentrations (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4).
Der er ikke set/forventet nogen signifikant interaktion. 
No significant interaction seen/expected.
Den dosisbegrænsende bivirkning var ortostatisk hypotension. 
The dose limiting adverse reaction was postural hypotension.
Middel ændring fra baseline (log kopier/ml) Procentdel af patienter med hiv 1-RNA < 400 kopier/ml 
Mean change from baseline (log copies/mL) Percentage of patients with HIV-1 RNA <400 copies/mL
På baggrund af hæmningsgraden af atazanavir/ritonavir eller darunavir/ritonavir i fravær af efavirenz, forventes en øget eksponering. 
Based on the extent of inhibition by atazanavir/ritonavir or darunavir/ritonavir in the absence of efavirenz, an increased exposure is expected.
In vivo Behandlingserfarne Voksne Patienter 
In vivo Treatment-Experienced Adult Patients
Udseende og pakningsstørrelser Celsentri filmovertrukne tabletter er blå og mærket ”MVC 25”, ”MVC 75”, MVC 150” eller ”MVC 
CELSENTRI film-coated tablets are blue coloured with “MVC 25”, “MVC 75”, “MVC 150” or “MVC 300”.
Behandlingserfarne Pædiatriske Patienter 
Treatment-Experienced Paediatric Patients
Viral tropisme kan ikke med sikkerhed forudsiges af behandlingsanamnesen eller vurderes på opbevarede blodprøver. 
The viral tropism cannot be safely predicted by treatment history and assessment of stored samples.
Den gennemsnitlige maraviroc-koncentration (Cavg) over 24 timer var 445,1 ng/ml; 338,3 ng/ml og 223,7 ng/ml for hhv. patienter med normal, let nedsat og moderat nedsat nyrefunktion. 
The average concentration (Cavg) of maraviroc over 24 hours was 445.1 ng/mL, 338.3 ng/mL, and 223.7 ng/mL for subjects with normal renal function, mild renal impairment, and moderate renal impairment, respectively.
Placebo+OB N=209 
Placebo + OBT N = 209
Patienter med kardiovaskulær comorbiditet kan have øget risiko for kardiovaskulære bivirkninger udløst af ortostatisk hypotension. 
Patients with cardiovascular co-morbidities could be at increased risk of cardiovascular adverse reactions triggered by postural hypotension.
Det gennemsnitlige geometriske forhold for Cmax og AUClast var henholdsvis 11 % og 25 % højere for forsøgspersoner med mild nedsat leverfunktion, og henholdsvis 32 % og 46 % højere for forsøgspersoner med moderat nedsat leverfunktion sammenlignet med forsøgspersoner med normal leverfunktion. 
Geometric mean ratios for Cmax and AUClast were 11% and 25% higher respectively for subjects with mild hepatic impairment, and 32% and 46% higher respectively for subjects with moderate hepatic impairment compared to subjects with normal hepatic function.
Hos voksne patienter med kreatininclearance < 80 ml/min, som også får potente CYP3A4-hæmmere, skal doseringen af maraviroc justeres til 150 mg 1 gang daglig (se pkt. 
In adult patients with a creatinine clearance of <80 mL/min, who are also receiving potent CYP3A4 inhibitors, the dose interval of maraviroc should be adjusted to 150 mg once daily (see sections 4.4 and 4.5).
Hos behandlingsnaive patienter blev der set samme lave forekomst i maravirocgruppen og kontrolgruppen (efavirenz). 
In treatment-naïve patients such events occurred at a similarly low rate with maraviroc and control (efavirenz).
Denne risiko skyldes en potentiel stigning i maraviroc-maksimumkoncentrationen, når maraviroc gives sammen med potente CYP3A-hæmmere eller boostede proteasehæmmere hos disse patienter. 
This risk is due to potential increases in maraviroc maximum concentrations when maraviroc is co-administered with potent CYP3A inhibitors or boosted PIs in these patients.
Hvis du får nogen symptomer på infektion, eller hvis du bemærker nogen af ovennævnte symptomer: Fortæl det straks til lægen. 
If you get any symptoms of infection or if you notice any of the symptoms above:
Geometrisk gennemsnitsændring hvis ikke andet er angivet 
Effects on active substance levels Geometric mean change if not stated otherwise
I cellekultur var kombinationen af maraviroc og andre antiretrovirale lægemidler ikke antagonistisk med en række NRTI, NNRTI, proteasehæmmere eller hiv-fusionshæmmeren enfuvirtid. 
When used with other antiretroviral medicinal products in cell culture, the combination of maraviroc was not antagonistic with a range of NRTIs, NNRTIs, PIs or the HIV fusion inhibitor enfuvirtide.
Baggrundsresistens over for andre klasser af antiretrovirale lægemidler har vist sig at være den samme hos tidligere ikke påvist CXCR4-tropisme virus hos den lave viralpopulation, som det, der blev fundet i CCR5-tropisme virus. 
Background resistance to other classes of antiretrovirals have been shown to be similar in previously undetected CXCR4-tropic virus of the minor viral population, as that found in CCR5-tropic virus.
Pegyleret interferon er ikke undersøgt. 
Pegylated interferon has not been studied, no interaction is expected.
Maraviroc-resistent virus forbliver CCR5-tropisme, og der er ingen konversion fra CCR5-tropisme virus til CXCR4-using virus. 
The maravirocresistant viruses remained CCR5-tropic and there was no conversion from a CCR5-tropic virus to a CXCR4-using virus.
Hver filmovertrukken tablet indeholder enten 25 mg, 75 mg, 150 mg eller 300 mg maraviroc. 
Each film-coated tablet contains 25 mg, 75 mg, 150 mg or 300 mg of maraviroc.
Maraviroc-resistente virus, der opstår in vitro forbliver følsomme over for fusionshæmmeren enfuvirtid og PIen, saquinavir. 
Maraviroc-resistant viruses that emerged in vitro remained sensitive to the fusion inhibitor enfuvirtide and the PI, saquinavir.
Intensiv farmakokinetik for maraviroc blev evalueret hos 50 behandlingserfarne, hiv 1-inficerede pædiatriske patienter i alderen 2 til 18 år (vægt fra 10,0 til 57,6 kg) med CCR5-tropisme i dosisbestemmelsesfasen af det kliniske studie A4001031. 
Intensive pharmacokinetics of maraviroc were evaluated in 50 treatment-experienced, CCR5tropic, HIV-1 infected paediatric patients aged 2 to 18 years (weight 10.0 to 57.6 kg) in the dosefinding stage of clinical trial A4001031.
Der er begrænsede data fra patienter med samtidig hepatitis B- og/eller C-virusinfektion (se pkt. 
There are limited data in patients with hepatitis B and/or C virus co-infection (see section 5.1).
Maravirocs sikkerhed og virkning hos patienter med alvorlig underliggende leversygdom er ikke undersøgt specifikt. 
The safety and efficacy of maraviroc have not been specifically studied in patients with significant underlying liver disorders.
Den anbefalede dosis er 150 mg (med potent CYP3A-hæmmer med eller uden en potent CYP3Ainduktor), 300 mg (uden potente CYP3A-hæmmere eller -induktorer) eller 600 mg Celsentri 2 gange daglig (med potent CYP3A-induktor uden en potent CYP3A-hæmmer) afhængig af interaktion med samtidig antiretroviralbehandling og anden medicin (se pkt. 
The recommended dose of CELSENTRI is 150 mg (with potent CYP3A inhibitor with or without a potent CYP3A inducer), 300 mg (without potent CYP3A inhibitors or inducers) or 600 mg twice daily (with potent CYP3A inducer without a potent CYP3A inhibitor) depending on interactions with concomitant antiretroviral therapy and other medicinal products (see section 4.5).
Fortæl lægen eller apotekspersonalet, hvis du (eller dit barn) begynder at tage ny medicin under behandling med Celsentri. 
Tell your doctor or pharmacist if you (or your child) begin taking a new medicine while taking CELSENTRI.
High density polyethylenflaske (HDPE) med børnesikret lukning indeholdende 230 ml maraviroc 20 mg/ml opløsning. 
High density polyethylene (HDPE) bottle, with a child resistant closure, containing 230 mL maraviroc 20 mg/mL solution.
Studiet A4001031 er et åbent multicenterstudie med pædiatriske patienter (i alderen 2 år til under 18 år), der er inficeret med CCR5-tropisme hiv 1, bestemt ved Trofile-assay for øget følsomhed. 
Study A4001031 is an open-label, multicenter trial in paediatric patients (aged 2 years to less than 18 years) infected with CCR5-tropic HIV-1, determined by the enhanced-sensitivity Trofile assay.
OB var valgt ud fra patienternes tidligere behandlingsanamnese og genotypisk og fænotypisk viral resistensbestemmelse ved baseline. 
The OBT was selected on the basis of the subject's prior treatment history and baseline genotypic and phenotypic viral resistance measurements.
Depression, søvnløshed 
Depression, insomnia common
Sådan skal du tage Celsentri 
How to take CELSENTRI
Pancytopeni, granulocytopeni 
Pancytopenia, granulocytopenia rare
Maraviroc tilhører en terapeutisk gruppe, som kaldes CCR5-antagonister. 
Maraviroc is a member of a therapeutic class called CCR5 antagonists.
• gulfarvning af huden eller det hvide i øjnene 
• yellowing of skin or eyes
Hvis du har taget eller givet for meget Celsentri Hvis du ved et uheld har taget eller givet for meget Celsentri: 
If you accidentally take or give too much CELSENTRI:
Fluconazol anses for at være en moderat CYP3A4-hæmmer. 
Fluconazole is considered to be a moderate CYP3A4 inhibitor.
På baggrund af hæmningsgraden af lopinavir/ritonavir, saquinavir/ritonavir eller atazanavir/ritonavir i fravær af efavirenz, forventes en øget eksponering. 
Based on the extent of inhibition by lopinavir/ritonavir, saquinavir/ritonavir or atazanavir/ritonavir in the absence of etravirine, an increased exposure is expected.
Ved initiering af antiretroviral kombinationsbehandling (CART) hos hiv-inficerede patienter med svær immuninsufficiens kan der opstå en inflammatorisk reaktion på asymptomatiske eller residuale opportunistiske patogener, som kan forårsage alvorlige kliniske tilstande eller forværring af symptomer. 
In HIV infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Patienterne blev randomiseret i forholdet 2:2:1, således at de enten fik maraviroc 300 mg (dosisækvivalens) 1 gang daglig, Celsentri 300 mg 2 gange daglig eller placebo i kombination med en optimal baggrundsbehandling (OB), der omfattede 3 til 6 antiretrovirale lægemidler (undtagen lavdosis ritonavir). 
Patients were randomised in a 2:2:1 ratio to maraviroc 300 mg (dose equivalence) once daily, twice daily or placebo in combination with an optimized background consisting of 3 to 6 antiretroviral medicinal products (excluding low-dose ritonavir).
Celsentri er, i kombination med andre antiretrovirale lægemidler, indiceret til behandlingserfarne, voksne, unge og børn på 2 år og derover, som vejer mindst 10 kg og er smittet kun med hiv 1-virus med verificeret CCR5-tropisme (se pkt. 
CELSENTRI, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adults, adolescents and children of 2 years of age, and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable (see sections 4.2 and 5.1).
• nyreproblemer. 
• kidney problems.
Forskellen i eksponering for maraviroc mellem ekstensive og dårlige metabolisatorer af CYP3A5 blev reduceret, når maraviroc blev anvendt sammen med en stærk CYP3A-hæmmer: ekstensive CYP3A5-metabolisatorer (n = 12) havde en 17 % lavere AUC for maraviroc sammenlignet med dårlige CYP3A5-metabolisatorer (n = 11), når maraviroc 150 mg blev givet én gang dagligt sammen med darunavir/cobicistat (800/150 mg). 
The difference in maraviroc exposure between CYP3A5 extensive and poor metabolisers was reduced when maraviroc was administered together with a strong CYP3A inhibitor: extensive CYP3A5 metabolisers (n=12) had a 17% lower maraviroc AUC compared with poor CYP3A5 metabolisers (n=11) when dosed with maraviroc 150 mg once daily in the presence of darunavir/cobicistat (800/150 mg).
Inden behandling med dette lægemiddel skal du fortælle det til lægen, hvis du (eller dit barn) har eller tidligere har haft nogle af følgende lidelser: 
Before taking this medicine, make sure that your doctor knows if you (or your child) have or in the past had any of the following:
Den kliniske effekt af maraviroc (i kombination med andre antiretrovirale lægemidler) på plasma-hivRNA-koncentrationer og CD4+-celletal er undersøgt i to pivotale, randomiserede, dobbeltblindede, multicenterstudier (MOTIVATE 1 og MOTIVATE 2, n=1.076) hos patienter inficeret med CCR5tropisme hiv 1-virus, bestemt ved Monogram Trofile-assay. 
The clinical efficacy of maraviroc (in combination with other antiretroviral medicinal products) on plasma HIV RNA levels and CD4+ cell counts have been investigated in two pivotal randomized, double blind, multicentre studies (MOTIVATE 1 and MOTIVATE 2, n=1076) in patients infected with CCR5 tropic HIV-1 as determined by the Monogram Trofile Assay.
Unge og børn fra 2 år, som vejer mindst 10 kg 
Adolescents and children from 2 years of age and weighing at least 10 kg
Celsentri 25 mg filmovertrukne tabletter EU/1/07/418/011 
CELSENTRI 25 mg film-coated tablets EU/1/07/418/011
Lot: 
Lot: {number}
• øget indhold i blodet af et stof, der kaldes CPK (som kan ses i blodprøver), hvilket er et tegn på, 
• an increase in a substance known as CPK (seen in blood test results) which is a sign that muscles are inflamed or damaged.
Der er øget risiko for ortostatisk hypotension hos patienter med alvorligt nedsat nyrefunktion, der behandles med potente CYP3A-hæmmere eller boostede proteasehæmmere og maraviroc. 
An increased risk of postural hypotension may occur in patients with severe renal insufficiency who are treated with potent CYP3A inhibitors or boosted protease inhibitors (PIs) and maraviroc.
I en retrospektiv analyse af MOTIVATE-studierne med en mere følsom analyse til screening for tropisme (Trofile ES) var responsraten (< 50 kopier/ml ved uge 48) 48,2 % hos patienter med kun CCR5-tropisk virus påvist ved baseline og behandlet med maraviroc + OB (n=328) og 16,3 % hos patienter behandlet med placebo+OB (n=178). 
In a retrospective analysis of the MOTIVATE studies with a more sensitive assay for screening of tropism (Trofile ES), the response rates (<50 copies/mL at week 48) in patients with only CCR5tropic virus detected at baseline was 48.2% in those treated with maraviroc + OBT (n=328), and 16.3% in those treated with placebo + OBT (n=178).
Tabel 1 Anbefalet doseringsregime til børn på 2 år og derover, som vejer mindst 10 kg 
Table 1 Recommended dosing regimen in children aged 2 years and above and weighing at least 10 kg
Farmakokinetiske populationsanalyser fra fase 3-studier tyder på dosisreduktion af maraviroc, da det giver passende maraviroceksponering, hvis det gives samtidig med indinavir. 
Population PK analysis in phase 3 studies suggests dose reduction of maraviroc when co-administered with indinavir gives appropriate maraviroc exposure.
Hos behandlingsnaive patienter var hepatobiliære lidelser ikke almindelige og ligeligt fordelt mellem de forskellige behandlingsgrupper (se pkt. 
Hepatobiliary disorders reported in treatment-naïve patients were uncommon and balanced between treatment groups (see section 4.8).
Den orale opløsning skal opbevares ved temperaturer under 30 °C. 
Store the oral solution below 30°C.
Placebo+OB 
Placebo + OBT
Celsentri indeholder et aktivt stof, der kaldes maraviroc. 
CELSENTRI contains a medicine called maraviroc.
• Aktivt stof: maraviroc. 
• The active ingredient in CELSENTRI is maraviroc.
Behandlingssvigt med CCR5-tropismevirus 
Failure with CCR5-tropic virus
Tabel 4: Hyppigheden ≥ 1 % af grad 3-4 anormaliteter (ACTG-kriterier) baseret på den maksimale grænse i laboratorieværdier uden hensyn til baseline studier MOTIVATE 1 og MOTIVATE 2 (puljede analyser op til 48 uger) 
Table 4: Incidence ≥1% of grade 3-4 abnormalities (ACTG criteria) based on maximum shift in laboratory test values without regard to baseline studies MOTIVATE 1 and MOTIVATE 2 (pooled analysis, up to 48 weeks)
I observationsfasen var forekomsten af disse valgte endepunkter for patienter behandlet med maraviroc i overensstemmelse med den forekomst, der er set på tidligere tidspunkter i studierne. 
The incidence of these selected endpoints for subjects on maraviroc in this observational phase was consistent with the incidence seen at earlier timepoints in the studies.
NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN ViiV Healthcare (logo) 
ViiV Healthcare (logo)
Der er ikke set nogen signifikant interaktion. 
No clinically significant interaction seen.
Etravirin og lopinavir/ritonavir, saquinavir/ritonavir eller atazanavir/ritonavir 
Etravirine and lopinavir/ritonavir, saquinavir/ritonavir or atazanavir/ritonavir
Tabel 6: Effektresultater ved 48 uger (puljede data fra studierne MOTIVATE 1 og MOTIVATE 2) 
Table 6: Efficacy Outcomes at week 48 (pooled studies MOTIVATE 1 and MOTIVATE 2) Outcomes
Ved administration af maraviroc hos rotter ses thyroideaadenom, der er forbundet med adaptive leverændringer ved en systemisk eksponering, der er 21 gange den forventede humane dosis. 
In rats, administration of maraviroc at a systemic exposure 21-times the expected human exposure produced thyroid adenomas associated with adaptive liver changes.
Inden for hver gruppe af bivirkninger med samme frekvens, er bivirkningerne opstillet efter, hvor alvorlige bivirkningerne er. 
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
België/Belgique/Belgien ViiV Healthcare sprl/bvba. 
ViiV Healthcare sprl/bvba .
Efavirenz og atazanavir/ritonavir eller darunavir/ritonavir 
Efavirenz and atazanavir/ritonavir or darunavir/ritonavir
Derudover er der i studier med behandlingserfarne forsøgspersoner med hiv-infektion set et øget antal leverpåvirkninger med maraviroc, men der var ikke en samlet stigning i ACTG-grad 3-4 anormalitet i leverfunktionsprøverne (se pkt. 
In addition, an increase in hepatic adverse reactions with maraviroc was observed during studies of treatment-experienced subjects with HIV infection, although there was no overall increase in ACTG Grade 3/4 liver function test abnormalities (see section 4.8).
Maraviroc metaboliseres af CYP3A4 og CYP3A5. 
Maraviroc is metabolised by cytochrome P450 CYP3A4 and CYP3A5.
Vend flasken med bunden opad. 
Turn the bottle upside down.
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Holland. 
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands.
Ved baseline var middel plasma hiv 1 RNA 4,3 log10 kopier/ml (interval 2,4 til 6,2 log10 kopier pr. ml), middel CD4+-celletal var 551 celler/mm3 (interval 1 til 1654 celler/mm3) og middel CD4+ % var 21 % (interval 0 % til 42 %). 
At baseline, mean plasma HIV-1 RNA was 4.3 log10 copies/mL (range 2.4 to 6.2 log10 copies per mL), mean CD4+ cell count was 551 cells/mm3 (range 1 to 1654 cells/mm3) and mean CD4+ % was 21% (range 0% to 42%).
Når rifabutin kombineres med en proteasehæmmer, som er en potent hæmmer af CYP3A4, forventes en netto hæmmende virkning på maraviroc. 
When combining rifabutin with protease inhibitors that are potent inhibitors of CYP3A4 a net inhibitory effect on maraviroc is expected.
Hos patienter med moderat nedsat nyrefunktion var Cavg for maraviroc lav fra 24-48 timer (Cavg: 32,8 ng/ml). 
The Cavg of maraviroc from 24-48 hours for subjects with moderate renal impairment was low (Cavg: 32.8 ng/mL).
Cancer i galdegange, diffust storcellet B-celle lymfom, Hodgkins sygdom, knoglemetastaser, levermetastaser, metastaser i peritoneum, kræft i næsesvælget, øsofagal karcinom 
Bile duct cancer, diffuse large B-cell lymphoma, Hodgkin's disease, metastases to bone, metastases to liver, metastases to peritoneum, nasopharyngeal cancer, oesophageal carcinoma rare
In vitro har maraviroc ingen aktivitet mod virus, der bruger CXCR4 som deres indtrædende coreceptor (dual-tropisme eller CXCR4-tropisme, der tilsammen benævnes CXCR4-using virus, se nedenfor). 
Maraviroc has no antiviral activity in vitro against viruses which can use CXCR4 as their entry coreceptor (dual-tropic or CXCR4-tropic viruses, collectively termed ‘CXCR4-using' virus below).
Der er udført præ- og postnatale udviklingsstudier i rotter i doser op til 27 gange det estimerede frie kliniske AUC ved en dosis på 300 mg 2 gange daglig. 
Pre- and post-natal developmental studies were performed in rats at doses up to 27-fold the estimated free clinical AUC for a 300 mg twice daily dose.
Toksisk hepatitis, leversvigt, levercirrose, forhøjet blod-phosphatase 
Hepatitis toxic, hepatic failure, hepatic cirrhosis, blood alkaline phosphatase increased rare
Celsentri bør anvendes med forsigtighed hos voksne patienter med alvorligt nedsat nyrefunktion (kreatininclearance < 30 ml/min), som får potente CYP3A4-hæmmere (se pkt. 
CELSENTRI should be used with caution in adult patients with severe renal impairment (CLcr <30 mL/min) who are receiving potent CYP3A4 inhibitors (see sections 4.4 and 5.2).
• krampestillende medicin (carbamazepin, phenytoin, phenobarbital). 
• anticonvulsant medicines (carbamazepine, phenytoin, phenobarbital).